 NEW YORK and LONDON, March 04, 2020 GLOBE NEWSWIRE -- Akari Therapeutics, Plc AKTX, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, today announced it had closed its previously announced private placement, issuing an aggregate of 5,620,296 American Depositary Shares the ADSs at 1.70 per ADS for aggregate gross proceeds of approximately 9.5 million to certain accredited and institutional investors, led by existing investors of the Company, including Dr. Ray Prudo, the Companys Chairman. This press release shall not constitute an offer to sell or the solicitation to buy nor shall there be any sale of the ADSs or warrants in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 